RNA-sequencing (RNA-seq) is a powerful technique to investigate the complexity of gene expression in the human brain. We used RNA-seq to survey the brain transcriptome in high-quality postmortem dorsolateral prefrontal cortex from 11 individuals diagnosed with bipolar disorder (BD) and from 11 age-and gender-matched controls. Deep sequencing was performed, with over 350 million reads per specimen. At a false discovery rate of o5%, we detected five differentially expressed (DE) genes and 12 DE transcripts, most of which have not been previously implicated in BD. Among these, Prominin 1/CD133 and ATP-binding cassette-sub-family G-member2 (ABCG2) have important roles in neuroplasticity. We also show for the first time differential expression of long noncoding RNAs (lncRNAs) in BD. DE transcripts include those of serine/arginine-rich splicing factor 5 (SRSF5) and regulatory factor X4 (RFX4), which along with lncRNAs have a role in mammalian circadian rhythms. The DE genes were significantly enriched for several Gene Ontology categories. Of these, genes involved with GTPase binding were also enriched for BD-associated SNPs from previous genome-wide association studies, suggesting that differential expression of these genes is not simply a consequence of BD or its treatment. Many of these findings were replicated by microarray in an independent sample of 60 cases and controls. These results highlight common pathways for inherited and non-inherited influences on disease risk that may constitute good targets for novel therapies.
INTRODUCTION
Gene expression profiling studies using microarray technology on postmortem brain tissues have identified a number of differentially expressed (DE) genes in bipolar disorder (BD), but with limited overlap of findings across studies. [1] [2] [3] [4] [5] The available microarray technology lacks sensitivity for low-abundance mRNA and may miss differentially spliced genes and isoforms that might have relevance to disease risk and progression. RNA-sequencing (RNA-seq) involves massively parallel sequencing of the transcribed portion of the genome, providing a direct estimate of transcript abundance, with counts proportional to the absolute abundance of target. Differential expression can be measured at various levels (gene, transcript, exon and so on) that may reflect alternative splicing and other important regulatory phenomena. For these reasons, RNA-seq is sensitive to low-abundance genes and transcripts not well represented on microarrays. 6 As sequence data is not limited by known gene annotations, novel genes can also be detected. 7 Here we report findings from the first RNA-seq-based survey of the brain transcriptome in high-quality postmortem brain tissue derived from two independent sets of individuals diagnosed with BD along with controls who were carefully matched for age and gender. In this initial analysis, we have focused on known genes and transcripts. The results, which were largely replicated in a microarray study in an independent sample, demonstrate that genes involved in neuroplasticity, circadian rhythms and GTPase binding are DE in BD and may contribute to disease risk.
MATERIALS AND METHODS Samples
Total RNA extracted from the dorsolateral prefrontal cortex (DLPFC) (Brodmann area 46) of postmortem brain tissue of 11 BD cases and 8 psychiatrically healthy controls was obtained from the Stanley Medical Research Institute (www.stanleyresearch.org). Additional total RNA 1 specimens prepared from the same region of postmortem brain from three psychiatrically healthy controls were provided by the Clinical Brain Disorders Branch, National Institute of Mental Health (NIMH) with informed consent from the legal next of kin under NIMH protocol 90-M-0142. Clinical characterization, neuropathological screening, toxicological analyses and dissections of the DLPFC for Clinical Brain Disorders Branch postmortem brains were previously described. 8 Cases and controls were matched on age and gender (Supplementary Table 1 ). All specimens had an RNA integrity number (RIN) ⩾6.0, except one case with a RIN of 4.9 that was dropped from analysis (see below).
RNA-seq
RNA-seq was performed at National Institutes of Health (NIH) Intramural Sequencing Center (NISC) that included library preparation, fragmentation and PCR enrichment of target RNA according to standard protocols. The first batch of specimens (five BD cases and five controls), referred to herein as 'NISC1', underwent paired-end sequencing on five lanes (one lane of 51 bp reads and four lanes of 76 bp reads) of the Illumina GA-IIx system (Illumina, San Diego, CA, USA). The second batch of six cases and six controls, referred to herein as 'NISC2', was sequenced on one lane (100 bp reads) of the Illumina HiSeq system (Illumina).
Gene-level analysis FASTQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and FASTX-toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) were used to examine the quality and trim reads. Paired-end reads were aligned to human genome build 19 using TopHat (TopHat version 2.0.4; http://tophat. cbcb.umd.edu/). 9 All NISC1 and NISC2 samples passed quality control (QC) except one case ('BP5') that had RINo 7; it was excluded from further analysis. For the gene-level analysis, a gene was considered the union of all its exons in any known isoforms, based on ENSEMBL annotation. Using HTSeq (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html), read counts were generated for genes on the Ensemble.gtf file downloaded from UCSC genome browser (http://genome.ucsc.edu/). Any reads that fell in multiple genes or in genes that mapped to the sex chromosomes were excluded from the analysis. We included all genes with >5 reads in at least four BD cases and four controls in NISC1 and NISC2, which is a minimum of 20 reads per group. To minimize outlier effects, we excluded any genes with variance ≥1 in the log 2 reads per million values within cases or controls.
Transcript-level analysis
The reads from NISC1 and NISC2 were mapped to the human genome build 19 Ensemble transcriptome using Bowtie (Bowtie version 0.12.8; http://bowtie-bio.sourceforge.net/index.shtml). 10 Read counts for each of the Ensemble transcripts were estimated by eXpress 11 (http://bio.math. berkeley.edu/eXpress/overview.html) using default parameters. eXpress differentiates between exons assigned to a particular isoform which it counts uniquely. Exons that are shared are partitioned among all isoforms, based on an EM algorithm, thus avoiding double counting of reads for a shared exon. Only those transcripts that map to autosomes were included in the analysis. All transcripts with read counts >5 in at least four BD cases and four controls in NISC1 and NISC2 were included.
Differential expression
Count data for genes and transcripts were analyzed in R using DESeq (http://www-huber.embl.de/users/anders/DESeq/) software package 12 with default settings. Normalization was done within DESeq. NISC1 and NISC2 samples were analyzed separately because of technical differences in sequencing methods (see above).
Meta-analysis
There was a highly significant correlation in log 2 fold change values of genes that passed quality control in both NISC1 and NISC2 (r = 0.3, Po0.0001; Figure 1 ). Thus, to improve the statistical power to detect disease-related differences in these samples, meta-analysis was performed. P-values obtained from DESeq were converted to Z-scores and combined across NISC1 and NISC2 using the Liptak-Stouffer method, 13 taking into account the direction of the fold change and weighting by sample size. The total weighted Z-score was then corrected to a mean of 1 and converted to a two-tailed P-value according to the standard normal distribution.
Technical validation
We selected 41 genes that were significant in the NISC1 gene-level analysis for validation by digital molecular barcoding using the Nanostring nCounter system (http://www.nanostring.com/) following the manufacturer-recommended protocol. Any probes that were not unique to our genes of interest were excluded before the experimental validation. Six housekeeping genes were included for data normalization.
Gene expression microarrays
Microarray gene expression profiling was performed using Illumina HumanHT-12_V4 chips (Illumina) on independent postmortem brain samples composed of 30 BD cases and 30 psychiatrically healthy controls (RIN ⩾ 7) from the "array collection" of the Stanley Medical Research Institute, Rockville, MD, USA.
Microarray data analysis
Microarray data were analyzed using 'R' (www.cran.r-project.org). The data analysis flowchart and QC plots are shown in Supplementary Figure 1 . Any gene probes that had >80% failure (that is, mean expression value ⩽7.75; Supplementary Figure 1E ) in cases or controls were removed, leaving 11 943 probes quantifying 8969 genes for analysis. Only autosomal genes were included in the analysis. After QC, quantile normalized data from 22 cases and 26 controls were analyzed for differential expression by analysis of covariance correcting for differences in age, gender, race, postmortem interval, brain pH and refrigerator index.
Quantitative PCR validation of microarray data Fifteen DE genes from the microarray analysis were validated using quantitative PCR on a Roche Lightcycler480 (Roche Applied Science, Indianapolis, IN, USA) using a standard protocol. The primer sequences used in this experiment are listed in Supplementary Table 2. The raw data was normalized to the geometric mean of the two housekeeping genes that met the criteria of no difference between the groups under examination. All measurements were performed in triplicate and the resulting data were analyzed using the ΔCt method.
Functional analysis
DE genes and transcripts with meta P-valueo0.05 were subjected to functional annotation in DAVID (http://david.abcc.ncifcrf.gov/). 14, 15 All genes and transcripts in the RNA-seq data that passed QC were used as background in DAVID. We used high stringency criteria to select the significantly enriched Gene Ontology (GO) categories. Functional categories with a Benjamini q-value o 5% were considered to be significantly enriched. To confirm the results in a larger sample, the functional analysis was repeated after addition of DE genes (with fold change >1.25) identified in the microarray experiment.
Genome-wide association study enrichment testing
To identify genes that may have a causal role in BD, we performed genome-wide association study (GWAS) enrichment analysis, similar in principle to some published approaches. 16, 17 SNPs from a published GWAS meta-analysis study 18 were pruned for linkage disequilibrium (r 2 o0.5) by PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/). 19 For each gene within an enriched GO term category, we assigned SNPs that mapped within 110 kb upstream of the transcription start site and 40 kb downstream of the 3′ untranslated region. 20 We then determined the proportion of SNPs with a nominal association P-value o0.05 in the GWAS analysis. 18 We used 10 000 random draws from the GWAS data (with replacement) to determine the number of draws that included at least as many nominally associated SNPs as in the nonrandom set, providing an empirical GWAS enrichment P-value.
To manage multiple comparisons, we excluded from this analysis enriched GO term categories that overlapped by >80% at the gene level with other enriched GO term categories containing more genes. For example, genes assigned to the GO term categories 'phospholipase C activity (12 genes)', 'homophilic cell adhesion (35 genes)', 'potassium ion binding (36 genes)', 'cation binding (652 genes)' and 'metal ion binding (647 genes)' overlap >80% at the gene level with those assigned to 'ion binding (669 genes).' So instead of testing all six categories, we performed GWAS enrichment solely on 'ion binding.' The final reported enriched terms may not cover all important functional information, but this strategy strikes a balance between more comprehensive results and loss of power from multiple testing.
RESULTS
Read depth and mapping A total of~7.5 billion reads were generated in NISC1 and NISC2 (an average of 272 million reads/specimen in NISC1 and 419 million reads/specimen in NISC2). Approximately, 96% and 87% of the reads in NISC1 and NISC2, respectively, mapped to the UCSC human genome build 19. For downstream analysis, we included a total of~1.25 billion properly paired reads in NISC1 and~3.3 billion properly paired reads in NISC2 (Supplementary Table 3 ).
Basic statistics and principal component analysis
The first three principal components represent 64% and 67% of the variability in NISC1 and NISC2, respectively. When principal component 2 was plotted against principal component 3, there was a significant separation between the BD and healthy control groups in NISC1; similar, but nonsignificant, separation was observed in NISC2 (Supplementary Figure 2) . This analysis indicates that overall gene expression patterns differ between cases and controls but does not point to specific genes. Raw count data for all genes (N = 25 017) in each specimen are shown in Supplementary Figures 3 and 4 .
Differential expression in BD The high-sequencing depth in RNA-seq permitted the analysis of expression at two biological levels, genes and transcripts. At the gene level, all the exons assigned to multiple isoforms of a gene were included in the analysis. At the transcript level, exons belonging to a particular spliced isoform of a gene were included. In total, 25 017 genes and 182 884 transcripts were analyzed (Supplementary Table 4 ). Figure 2 summarizes the overall results in a circos plot, 21 and our analysis pipeline is presented in Supplementary Figures 5a and 5b .
Gene-level analysis: DE genes Meta-analysis identified five DE genes at false discovery rate (FDR) o5%: LINC00173, Prominin 1 (PROM1), ATP-binding cassette-subfamily G-member2 (ABCG2), Alpha-2-macroglobulin (A2M) and Friend leukemia virus integration 1 (FLI1) ( Table 1) . Except for LINC00173, a long noncoding RNA (lncRNA), all of these genes 18 linked to DE genes and transcripts; at the core, green radii connect genes involved in ion binding and black radii connect genes involved in regulation of cell development.
were downregulated in BD cases relative to healthy controls (Supplementary Figure 6) . A total of 1225 genes were shown to have a nominal meta-analysis P-value o0.05 (Supplementary Table 5 ). A volcano plot of log 2 fold change versus the metaanalysis P-value for all genes that passed quality control is presented in Figure 3a . Heatmaps and parallel plots for each sample are presented in Supplementary Figures 7 and 8 , and the corresponding genes are shown in Supplementary Tables 6 and 7 .
Transcript-level analysis: DE transcripts Overall, 12 transcripts were DE at FDR o 5% in the meta-analysis (Table 1 and Supplementary Figure 9) , of which eight transcripts were downregulated. Supplementary Figures 10 and 11 represent the heatmaps and parallel plots of all transcripts with P-value o 0.05 in NISC1 and NISC2, respectively. The DE transcripts with P o 0.05 in each sample are listed in Supplementary  Tables 8 and 9 . Overall, 2776 DE transcripts encoded by 2280 unique genes had a meta-analysis P-value o 0.05 (Supplementary Table 5 ). Figure 3b depicts all transcripts that passed QC along with log 2 fold changes and meta-analysis P-values.
Gene-and transcript analysis overlap Transcript-level analysis of 1225 DE genes revealed that 358 genes have DE isoforms (Supplementary Table 5 ). This overlap between gene-and transcript-level analyses was highly significant (hypergeometric P-value o10 − 16 ) with an odds ratio of 3.85. A range of 1-5 DE isoforms were observed per gene. This illustrates the degree of complexity in regulation of the brain transcriptome as revealed through RNA-seq.
Technical validation of RNA-seq data The correlation coefficient for log 2 fold change between RNA-seq and Nanostring was 0.72 (P o0.0001), indicating a good Base mean = number of reads/ normalization constant of the sample. Figure 3. (a, b) Volcano plots generated by meta-analysis of differential gene expression at the level of gene and transcript. The x axis shows the weighted average meta log 2 fold change across both National Institutes of Health (NIH) Intramural Sequencing Center (NISC)-1 and NISC2 samples. The meta-analysis P-value (-log base 10) for differential expression is plotted on the y axis. At a nominal meta-analysis P-valueo 0.05, downregulated genes (blue dots) and upregulated genes (red dots) are represented. The larger dots indicate genes DE at false discovery rate (FDR) o5% (corresponding to a P-value o0.000012). All other genes that passed quality control are shown as gray dots.
agreement. A scatterplot of normalized counts from RNA-seq versus Nanostring is shown in Supplementary Figure 12 .
Microarray results and comparison with RNA-seq We compared the RNA-seq (gene-and transcript level) results with those obtained in a gene expression microarray study of an independent sample of 22 BD cases and 26 controls. Out of 8969 genes that passed QC by RNA-seq, 1357 genes were DE in the microarray data by RNA-seq (Supplementary Table 10 ) with RNA-seq data. These results provide additional validation for the RNA-seq data and independent replication for a significant subset of the findings.
Quantitative PCR results
Of the 15 DE genes in microarray data validated by quantitative PCR, 13 genes were concordant in direction of fold change with the microarray data and 2 genes were discordant (Pearson correlation = 0.83, P-value = 0.00012; Supplementary Table 11 ).
GO analysis
Functional enrichment analysis was performed on 1225 DE genes and 2776 DE transcripts. This analysis revealed significant enrichment for 16 GO categories at a Benjamini q-value o5% (Table 2) . We found >5-fold enrichment in 'transmembrane receptor protein phosphatase activity'; >2-fold enrichment in 'regulation of transmission of nerve impulse', 'GTPase binding', 'regulation of cyclic nucleotide metabolic process' and 'cell part morphogenesis'. These results successfully replicated when we added the DE genes from the microarray experiment (Table 2) .
GWAS enrichment analysis
In order to distinguish between potentially causal genes and those whose differential expression may be a consequence of BD or its treatment, we tested genes assigned to enriched GO categories for enrichment of nominally associated SNPs in a recent GWAS of BD. 18 We detected significant enrichment of small association P-values for SNPs near genes assigned to five GO categories: 'cell fraction', 'GTPase binding', 'nucleoside-triphosphatase regulator activity', 'ion binding' and 'passive transmembrane transporter activity' ( Table 2 ). The remaining categories showed no GWAS enrichment. The GWAS enrichment results were strengthened by addition of genes identified in the microarray experiment. All the GO categories that showed GWAS enrichment in the RNA-seq data were also significantly enriched after addition of the microarray data (Table 2) .
DISCUSSION
To our knowledge, this is the first RNA-seq based profiling of the brain transcriptome in BD. The results demonstrate that a number of genes and transcripts are DE in brain tissue of people with BD. Some of these genes were previously implicated in genetic association or gene expression studies of BD. [22] [23] [24] [25] [26] [27] [28] [29] [30] The DE genes are significantly enriched for several GO categories. Genes involved in 5 of these functional categories are also enriched for GWAS signals, suggesting a causal role in risk for BD. These results were also supported by microarray data in a larger and independent sample.
A few individual gene-and transcript findings merit discussion. PROM1/CD133 and ABCG2 were both significantly under expressed in BD. Both genes are strongly expressed in neural stem cells and other highly plastic tissues. 31, 32 This finding is consistent with the idea of reduced neuroplasticity in BD. Another top finding is underexpression in BD of the FLI1/ERGB gene. Defects in FLI1 cause significant defects in neural crest development. 33 We found several lncRNAs to be DE in BD. This finding highlights a unique attribute of RNA-seq for transcriptome analysis, as lncRNAs are not detected by conventional microarray chips. Coon et al. 34 showed that lncRNAs have a role in the vertebrate circadian cycle that is known to be disrupted during BD episodes. Previous studies have also shown that altered expression of lncRNAs may have a role in several neurological and neuropsychiatric diseases. [35] [36] [37] [38] [39] The high depth of sequencing in RNA-seq uncovered multiple DE transcripts. Although, several of these are novel in BD, some have been previously implicated in related phenotypes. Oxysterol binding protein-like 3 (OSBPL3) is disrupted by sleep deprivation in model organisms. 40, 41 Glucosidase alpha neutral AB (GANAB) is DE in DLPFC in schizophrenia, 42 and is one of several genes implicated in synaptic dysfunction in that disorder. 43 Serine/ arginine-rich splicing factor 5 (SRSF5) has a role in circadian regulation. 44 Proteins encoded by regulatory factor X4 (RFX4) have also been shown to be involved in circadian rhythms in mammals, 45 and the gene was implicated in BD by Glaser et al.
46
Differential expression of transcripts may reflect differential exon usage related to alternative splicing, variable transcription start sites or other mechanisms. We do not present an exon-level analysis here, as the available sample size was limited and the analysis tools are still evolving rapidly. We did observe good agreement in differential expression at the gene-and transcript levels, but in some instances the gene-and transcript-level expression appeared to vary in opposite directions. Most of these disordered expression patterns did not replicate between NISC1 and NISC2 and may thus reflect false positives.
Differential splicing in brain is strongly influenced by RNA binding proteins such as Fox1 and Fox2 47 encoded by RBFOX1 (A2BP1) and RBFOX2, respectively. Both proteins are preferentially expressed in brain and muscle. Deletions of RBFOX1 have been found in autism and schizophrenia, 48 ,49 abnormal brain expression of A2BP1 has been reported in autism 17 and common variation in RBFOX1 has been implicated in BD. 50 We examined the overlap between DE transcripts in this study and predicted targets of Fox-1/Fox2 in humans. 47, 51 A significant minority of the DE transcripts we detected overlap with identified Fox1/Fox2 targets; an overlap not seen with the list of DE genes. This suggests that transcriptome dysregulation in BD differs at the gene-and transcript levels, and that the latter is related to Fox1/ Fox2.
At the pathway level, our results not surprisingly point to several functions important in brain development and function. On the other hand, the GWAS enrichment analysis suggested that genes involved in second-messenger signaling (GTPase binding and nucleoside-triphosphatase regulator activity) have a causal role in BD. These results are consistent with the large body of evidence implicating second-messenger systems in BD. 52 GTPases are often highly 'druggable' targets, so may be particularly promising leads for the development of novel therapeutics.
In contrast to some previous studies, we found a strong correlation between the RNA-seq results and those obtained from microarray analysis. This may reflect the higher precision and lower technical variability of RNA-seq data. 53 Another advantage of RNA-seq is that it can capture genes expressed over a wide dynamic range. We captured some genes and transcripts expressed at ⩽100 reads and some with ⩾30 000 reads, a~300-fold dynamic range.
The main limitations of this study derive from our necessary reliance on postmortem brain tissue that is subject to agonal and postmortem variables that are difficult to control, along with individual differences in experience, health and medication treatment. 54 However, it is very unlikely that the majority of the expression changes we observed can be attributed to such confounding. Many of the gene-level findings were supported in three independent samples and by two different methods, RNA-seq and microarray. Further, we carefully matched BD cases and controls on age and sex, and included only those tissue samples with the highest quality RNA. We also detected enrichment of GWAS signals in several groups of DE genes and transcripts this is inconsistent with a secondary effect of confounding variables.
We focused only on one brain region, chosen based on prior evidence of involvement of DLPFC in BD. 55 Studies of additional brain regions are needed and may point to different genes and additional pathways. We also did not attempt to differentiate among RNA derived from the distinct cell types that comprise DLPFC. As single-cell sequencing technology advances, this will be the next step for RNA-seq studies, enabling even greater precision than was possible here.
Our findings implicate novel genes in BD and may point to novel therapeutic targets. These RNA-seq data may also support additional inferences about novel genes, RNA-editing and allele-specific expression that we did not pursue in this study. Methods for such analyses remain under development, and larger samples than we had available may be needed. We have probably uncovered only a fraction of what these data may reveal about BD. We have submitted our raw data to the Stanley Medical Research Institute and Gene Expression Omnibus (GEO: GSE53239) where they are available upon request for further studies. 
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